Leiomyoma
diseaseOn this page
Also known as fibroidfibroid neoplasmfibroid tumorfibroid tumourleiomyoma, benignleiomyomatous neoplasm (morphologic abnormality)leiomyomatous tumour
Summary
Leiomyoma (MONDO:0001572) is a disease (an umbrella term covering 30 Mondo subtypes) and 122 clinical trials. Top therapeutic interventions include ulipristal acetate, leuprolide, and ulipristal. A subtype of benign smooth muscle neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 30 Mondo subtypes
- Clinical trials: 122
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | leiomyoma |
| Mondo ID | MONDO:0001572 |
| MeSH | D007889 |
| DOID | DOID:127 |
| NCIT | C3157 |
| SNOMED CT | 146801000119103 |
| UMLS | C0023267 |
| MedGen | 9710 |
| Is cancer (heuristic) | no |
Also known as: fibroid · fibroid neoplasm · fibroid tumor · fibroid tumour · leiomyoma, benign · leiomyomatous neoplasm (morphologic abnormality) · leiomyomatous tumour
Data availability: 1 cell line.
Disease family
An umbrella term covering 30 Mondo subtypes.
Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system benign neoplasm › benign muscle neoplasm › benign smooth muscle neoplasm › leiomyoma
Subtypes (30): laryngeal leiomyoma, gastric leiomyoma, ureter leiomyoma, vaginal leiomyoma, bladder leiomyoma, breast leiomyoma, small intestine leiomyoma, urethra leiomyoma, trachea leiomyoma, prostate leiomyoma, mediastinum leiomyoma, fallopian tube leiomyoma, central nervous system leiomyoma, bizarre leiomyoma, deep leiomyoma, leiomyoma cutis, lung leiomyoma, pericardium leiomyoma, leiomyomatosis, cellular leiomyoma, gallbladder leiomyoma, vulvar leiomyoma, colorectal leiomyoma, liver leiomyoma, esophagus leiomyoma, renal leiomyoma, myofibroma, uterine corpus leiomyoma, leiomyoma of ciliary body, benign metastasizing leiomyoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved, 8 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Ulipristal Acetate | Approved (phase 4) |
| Asoprisnil | Phase 3 (in late-stage trials) |
| Dexamethasone | Phase 3 (in late-stage trials) |
| Leuprolide | Phase 3 (in late-stage trials) |
| Linzagolix | Phase 3 (in late-stage trials) |
| Mifepristone | Phase 3 (in late-stage trials) |
| Misoprostol | Phase 3 (in late-stage trials) |
| Sodium Chloride | Phase 3 (in late-stage trials) |
| Vilaprisan | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Lidocaine, Onabotulinumtoxina, Ropivacaine, Ulipristal, Vasopressin.
Clinical trials & evidence
Clinical trials
Clinical trials: 122.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 61 |
| PHASE4 | 18 |
| PHASE3 | 17 |
| PHASE2 | 16 |
| PHASE1 | 8 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06143631 | PHASE4 | RECRUITING | Prescription of Letrozole for Uterine Myoma |
| NCT00628901 | PHASE4 | COMPLETED | A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) |
| NCT00746031 | PHASE4 | COMPLETED | Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids |
| NCT00995878 | PHASE4 | COMPLETED | The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids. |
| NCT01344486 | PHASE4 | TERMINATED | Peritoneal Cavity Conditioning Decreases Pain, Inflammation and Adhesions |
| NCT02209545 | PHASE4 | TERMINATED | Misoprostol for Reduction of Blood Loss During Fibroid Surgery |
| NCT02288130 | PHASE4 | UNKNOWN | Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy |
| NCT02357563 | PHASE4 | UNKNOWN | Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation |
| NCT02361879 | PHASE4 | UNKNOWN | Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma |
| NCT02361905 | PHASE4 | UNKNOWN | Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas |
| NCT02470741 | PHASE4 | COMPLETED | Pilot of Letrozole for Uterine Myomas |
| NCT02620345 | PHASE4 | COMPLETED | Fibroids in Women of Reproductive Age and Women Pregnancy |
| NCT02812186 | PHASE4 | COMPLETED | Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery |
| NCT02825719 | PHASE4 | TERMINATED | Ulipristal Use in Chinese Population |
| NCT03815344 | PHASE4 | COMPLETED | Combined Vaginal Misoprostol and Perivascular Vasopressin |
| NCT03937401 | PHASE4 | UNKNOWN | Oxytocin in MRI-HIFU |
| NCT04145518 | PHASE4 | COMPLETED | Mechanistic Characterization of Uterine Pain |
| NCT05538689 | PHASE4 | WITHDRAWN | Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL) |
| NCT00100191 | PHASE3 | COMPLETED | Emmy Trial: Uterine Artery Embolization (UAE) Versus Hysterectomy for Uterine Fibroids |
| NCT00133705 | PHASE3 | COMPLETED | Trial of Mifepristone for Fibroids |
| NCT00152256 | PHASE3 | COMPLETED | A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids |
| NCT00152269 | PHASE3 | COMPLETED | Treatment of Uterine Fibroids With Asoprisnil(J867) |
| NCT00156156 | PHASE3 | COMPLETED | Study of Asoprisnil in the Treatment of Uterine Fibroids. |
| NCT00156195 | PHASE3 | COMPLETED | Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids |
| NCT00156208 | PHASE3 | COMPLETED | Safety of Treatment of Uterine Fibroids With Asoprisnil |
| NCT00160381 | PHASE3 | COMPLETED | A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids |
| NCT00821275 | PHASE2/PHASE3 | UNKNOWN | Clinical Trial of Uterine Artery Embolization for Uterine Leiomyoma |
| NCT01553123 | PHASE3 | WITHDRAWN | Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma |
| NCT01581944 | PHASE3 | COMPLETED | Gonadotropin-releasing Hormone Agonist Prior to Myomectomy |
| NCT02061657 | PHASE3 | COMPLETED | Impact of Misoprostol on Blood Loss In Myomectomy Operations |
| NCT02147158 | PHASE3 | COMPLETED | A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas |
| NCT02147197 | PHASE3 | COMPLETED | A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas |
| NCT02189083 | PHASE3 | COMPLETED | Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids |
| NCT03122782 | PHASE3 | UNKNOWN | Hemostatic Effect of Intrauterine Instillation Of Tranexamic Acid In Hysteroscopic Myomectomy |
| NCT04655144 | PHASE3 | COMPLETED | Dexamethasone for Post Uterine Artery Embolization Pain |
| NCT04849858 | PHASE3 | TERMINATED | Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures |
| NCT03400826 | PHASE2 | RECRUITING | Effects of Simvastatin on Uterine Leiomyoma Size |
| NCT00044876 | PHASE2 | COMPLETED | Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist |
| NCT00087841 | PHASE2 | COMPLETED | Self-Hypnotic Relaxation Therapy During Invasive Procedures |
| NCT00150644 | PHASE2 | COMPLETED | A Study to Evaluate the Effects of Asoprisnil(J867) in Women With Uterine Fibroids Who Are Scheduled for a Hysterectomy |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ULIPRISTAL ACETATE | 4 | 12 |
| LEUPROLIDE | 4 | 9 |
| ULIPRISTAL | 4 | 6 |
| GONADORELIN ACETATE | 4 | 2 |
| LETROZOLE | 4 | 2 |
| MIFEPRISTONE | 4 | 2 |
| MISOPROSTOL | 4 | 2 |
| ACETYLCHOLINE | 4 | 1 |
| FERROUS SULFATE | 4 | 1 |
| NAPROXEN SODIUM | 4 | 1 |
| NITROPRUSSIDE | 4 | 1 |
| OXYTOCIN | 4 | 1 |
| PIRFENIDONE | 4 | 1 |
| ROCURONIUM | 4 | 1 |
| TRANEXAMIC ACID | 4 | 1 |
| TRIPTORELIN | 4 | 1 |
| ASOPRISNIL | 3 | 9 |
| VILAPRISAN | 3 | 5 |
| PF-05019702 | 1 | 1 |
| CHEMBL2370644 | 0 | 2 |
| CHEMBL4064157 | 0 | 2 |
| CHEMBL4067090 | 0 | 1 |
| CHEMBL4303358 | 0 | 1 |
| MISOPROSTOL ACID | -1 | 3 |